Biotech entity
Against the same-window beat baseline of 16% negative, this entity's 0% share is less negative. FDA is the most frequent co-covered peer, appearing in 4 of the 12 tracked stories. The 183-day window averages about 0.5 stories each week. The busiest single day carried 2.
Last mentioned: 3d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Against the same-window beat baseline of 16% negative, this entity's 0% share is less negative. FDA is the most frequent co-covered peer, appearing in 4 of the 12 tracked stories. The 183-day window averages about 0.5 stories each week. The busiest single day carried 2. Their average consequence score of 6.4 runs above the beat's 6.1 for that window. Source depth averages 3 original sources per story, versus 3.6 across the same-window beat baseline. Coverage clusters in fda-approval, which accounts for 6 of those 12, with the remainder spread across 1 other category. We currently track 12 Biotech stories that mention Moderna, published between February 18, 2026 and August 19, 2026.
Computed from the 12 stories linked to this entity, with beat comparisons drawn from all 763 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Moderna. Shared-story counts are live from our verified record — not editorial picks.
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
FDA Decision Deadline
The agency faces a deadline to approve or reject the vaccine.
FDA Approval of mRNA-1010
The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+.
Advisory Panel Recommends Approval
An FDA advisory panel votes in favor of approving the vaccine.
Court Ruling
Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul.
Settlement Reached
Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
Legal Challenge
The AAP and ACP file suit in Massachusetts federal court to block the changes.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
FDA Issues Refuse-to-File Letter
FDA informs Moderna it will not review the mRNA flu shot application, surprising the company after prior assurances.
FDA Accepts Application After Outcry
A little over a week later, the agency reverses its decision after Moderna commits to a confirmatory study.
Refusal to File
FDA issues a shocking rejection of the application, sparking a public dispute.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
Axsome full-year 2025 results
Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
Initial BLA Submission
Moderna submits its Biologics License Application for mRNA-1010.
BLA Submission
Moderna submits Biologics License Application for mRNA-1010.
Revolution Medicines mid-2025 data readout
RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
ACIP Restructuring
HHS replaces existing ACIP members with figures aligned with the administration's views.
Moderna appears on both MarketBeat's value and large-cap high-volume screens on August 19, underscoring unusual liquidity and renewed biotech interest despite a post-COVID valuation reset. The mRNA pipeline spans respiratory, latent, and public health vaccines, setting up multiple clinical catalysts.
Source: watchlistnews.com · tickerreport.com
Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza.
Source: livescience.com · MedPage Today
The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Source: kawc.org · wknofm.org
After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Source: news.wjct.org · wdiy.org
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Moderna (MRNA) shares rose significantly on March 4, 2026, as part of a broader market rally that lifted high-growth technology and clean energy stocks. The move highlights a renewed investor appetite for innovative platforms, signaling a potential recovery for the biotech sector following a period of macro-induced volatility.
Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Source: baltimoresun.com · beckershospitalreview.com
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.
Source: toronto.citynews.ca · bostonglobe.com
Moderna is linked from 12 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
